Eisai Co Ltd produces prescription drugs. The Company produces and sells diagnostic drugs. The Company also manufactures and sells foods, livestock feeds, chemicals, and agrochemicals.In December 2022, Catalyst Pharmaceuticals Inc entered into a definitive agreement with Eisai Co Ltd under which Catalyst will acquire the U.S. rights to FYCOMPA.In October 2020, Eisai Co Ltd and JD Health announced to acquire a joint venture company, Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China.In May 2019, the company had commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with the businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.In December 2015, Eisai Co entered into a business acquisition agreement with Alfresa Holdings